RT Journal Article
SR Electronic
T1 Projecting COVID-19 disease severity in cancer patients using purposefully-designed machine learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20179838
DO 10.1101/2020.08.23.20179838
A1 Saket Navlakha
A1 Sejal Morjaria
A1 Rocio Perez-Johnston
A1 Allen Zhang
A1 Ying Taur
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20179838.abstract
AB Background Accurately predicting outcomes for cancer patients with COVID-19 has been clinically challenging. Numerous clinical variables have been retrospectively associated with disease severity, but the predictive value of these variables, and how multiple variables interact to increase risk, remains unclear.Methods We used machine learning algorithms to predict COVID-19 severity in 354 cancer patients at Memorial Sloan Kettering Cancer Center in New York City. Using clinical variables only collected on or before a patient’s COVID-19 positive date (time zero), we sought to classify patients into one of three possible future outcomes: Severe-early (the patient required high levels of oxygen support within 3 days of being tested positive for COVID-19), Severe-late (the patient required high levels of oxygen after 3 days), and Non-severe (the patient never required oxygen support).Results Our algorithm classified patients into these classes with an AUROC ranging from 70-85%, significantly outperforming prior methods and univariate analyses. Critically, classification accuracy is highest when using a potpourri of clinical variables — including patient demographics, pre-existing diagnoses, laboratory and radiological work, and underlying cancer type — suggesting that COVID-19 in cancer patients comes with numerous, combinatorial risk factors.Conclusions Overall, we provide a computational tool that can identify high-risk patients early in their disease progression, which could aid in clinical decision-making and selecting treatment options.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSN thanks funding from the Simons Center for Quantitative Biology at Cold Spring Harbor Laboratory.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Memorial Sloan Kettering Cancer Center Institutional Review Board granted a Health Insurance Portability and Accountability Act waiver of authorization to conduct this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available following publication.